November 11, 2021

$14.9M Awarded to Lutz Lab’s COVID-19 Technology Company

Anavasi Diagnostics, a company recently founded out of Professor Barry Lutz’s lab at the University of Washington, announced it has been awarded $14.9 million from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative. The funding will accelerate the launch and broad market availability of the AscencioDx™ molecular diagnostic platform for the detection of RNA indicative of the SARS-CoV-2 / COVID-19 virus.

The project was initiated less than a year ago and advanced quickly with coaching and support from the WE-REACH team and the NIH RADx initiative. Learn  more about the exciting journey this team has been on as they moved their technology from university-based research to a funded commercial enterprise.